Moderna, Inc.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Moderna's moat is an mRNA design-and-manufacture platform that just produced the first positive Phase 3 individualized neoantigen cancer therapy — intismeran autogene, 50/50 with Merck — sitting on top of a still-resetting respiratory vaccine franchise. The platform is real and now clinically validated in adjuvant melanoma; it is not a patent fortress, and COVID IP was just settled for $950 million.
The competitive position rests on individualized neoantigen manufacturing plus a 50/50 Merck oncology collaboration, not on COVID vaccine share which has already collapsed:
- Intismeran: first Phase 3 mRNA cancer therapy: On August 19, 2026 Merck and Moderna reported that INTerpath-001 (1,137 patients, 2:1, resected stage IIB–IV melanoma) met recurrence-free survival and distant metastasis-free survival at a pre-specified interim versus KEYTRUDA alone — the first Phase 3 win for an individualized neoantigen therapy and the first to show a clinically meaningful improvement over KEYTRUDA monotherapy in adjuvant melanoma. Hazard ratios were not disclosed; full data go to a medical meeting and to regulators. Five-year Phase 2b (KEYNOTE-942) showed a 49% cut in recurrence or death (HR 0.51) and a 59% cut in distant metastasis or death (HR 0.411). Nine Phase 2/3 INTerpath trials are underway across melanoma, NSCLC, bladder cancer and renal cell carcinoma; adjuvant RCC Phase 2 is fully enrolled and may be the next readout.
- Personalized manufacturing, 50/50 with Merck: Each intismeran dose is built from a patient's tumor mutational signature — synthetic mRNA coding for up to 34 neoantigens inside Moderna's LNP. That workflow (sequencing → design → GMP batch per patient) is the switching cost, and it is also the scale risk: commercial adjuvant melanoma would require industrializing one-lot-per-patient manufacturing. Merck paid $250 million in 2022 to exercise its option; costs and profits are shared equally worldwide. Moderna does not own the oncology P&L outright, but it keeps the manufacturing node and the platform IP.
- Respiratory franchise after the COVID cliff: FY2025 revenue was $1.9 billion after the pandemic unwind. Spikevax, mNEXSPIKE and mRESVIA remain the cash products; mFLUSIVA (mRNA-1010) won FDA approval on August 5, 2026 for adults 50+ (traditional 50–64, accelerated 65+) for the 2026–27 season, and mCOMBRIAX (flu+COVID) is authorized in the EU. 2026 guidance is up to +10% growth, ~50/50 US/international, with ~55% of H2 recognized in Q3. Norovirus (mRNA-1403) missed early-success criteria at the Phase 3 interim and needs another cohort. The respiratory book funds the oncology build; it is not a growth engine on the scale of 2021–22.
- IP settlement and remaining legal drag: H1 2026 cost of sales included $884 million of royalties tied to a $950 million Arbutus/Genevant settlement paid in July. That cleared the largest LNP-patent overhang but left potential additional exposure of up to $1.3 billion and other ongoing litigation. Regulatory lock-in on approved vaccines is real; the COVID IP estate is no longer a free option.
Moat Verdict
Moderna is a net beneficiary of AI in the narrow sense that sequence-to-neoantigen design and trial operations compress with better models — that strengthens the process, it does not create a new moat. The AI-resilient pillars that actually matter are regulatory approvals on the respiratory franchise and the still-unapproved but now Phase-3-positive oncology dataset; both are intact, not strong. Talent and process knowledge are contestable. The COVID IP settlement showed the vulnerable side: LNP patents were never exclusive. Durability in the AI era depends on converting intismeran into approved, guideline-embedded therapy, not on software-style switching costs.
65.0 resilient · 65.0 vulnerable · 80/20 = 65.0 · = 65
Open a moat to read its note.
Physicians prescribe on trial evidence and guidelines, not a software workflow; interface learning costs do not apply to vaccines or individualized therapies.
The per-patient neoantigen design, LNP formulation and one-lot GMP workflow is vendor-owned process knowledge BioNTech and others can contest but cannot copy from a label. It is a real process moat, not a monopoly — Pfizer/BioNTech already commercialized mRNA at scale.
Moderna does not control access to a public data source; tumor sequencing for intismeran is patient-specific and contractual, not a public-data franchise.
mRNA design, LNP chemistry and personalized GMP remain specialist skills, but the post-COVID talent pool is deeper than in 2019 and BioNTech, Pfizer, CureVac and large-pharma mRNA groups compete for the same people.
Vaccines and individualized therapies are sold as labeled products, not a software-style suite; government respiratory contracts are procurement, not a bundle moat.
INTerpath-001 plus KEYNOTE-942 give Moderna and Merck the largest clinical neoantigen-response dataset in melanoma, and each commercial patient would add a tumor-to-dose record. That is compounding and hard to replicate quickly, but it is not yet a genetics-scale franchise on Regeneron Genetics Center terms — and Phase 3 HRs are still unpublished.
Spikevax, mNEXSPIKE, mRESVIA and now mFLUSIVA (FDA, Aug 5 2026) plus EU mCOMBRIAX are approved products with GMP and national-program placement. Intismeran is not yet approved. The $950M Arbutus/Genevant settlement removed the largest LNP-patent cloud but confirmed that the COVID IP estate was contestable, not a Lilly-style patent wall.
A weak data flywheel: more sequenced tumors and more T-cell-response outcomes should improve neoantigen selection. Prescriber experience with mRNA in oncology is still early. This is not a two-sided network.
Long-term government partnerships (UK, Canada, Australia) and EU joint procurement for mRESVIA embed the respiratory products in national immunization calendars. Intismeran would embed in adjuvant-melanoma pathways only after approval and guideline inclusion — that is still ahead.
Moderna is a drug and vaccine manufacturer, not the authoritative record for a customer's clinical or financial system.
Drug franchise economics come from patents and approvals (regulatoryLockIn), not a unit-cost lead from manufacturing scale.
Prescribing follows efficacy, label and formulary position, not the manufacturer's name; no brand premium independent of the approvals.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Moderna's moat is an mRNA design-and-manufacture platform that just produced the first positive Phase 3 individualized neoantigen cancer therapy — intismeran autogene, 50/50 with Merck — sitting on top of a still-resetting respiratory vaccine franchise. The platform is real and now clinically validated in adjuvant melanoma; it is not a patent fortress, and COVID IP was just settled for $950 million.
Growth Score
The 3–5 year growth path is no longer a COVID-decline story. FY2025 printed $1.9B; 2026 is guided up to +10% (~$2.1B) on international partnerships and mNEXSPIKE, with mFLUSIVA adding from the 2026–27 flu season. Intismeran is still pre-revenue — a 2027 filing and 2027–28 approval is the base path after today's Phase 3 hit — but a melanoma launch plus even one additional INTerpath indication would make oncology the second franchise by 2029. Q2 revenue was $145M (flat YoY) with a $(782)M GAAP loss ($(1.97)/sh); H1 revenue of $534M (+114%) is a seasonal-base effect, not the run-rate. Opex is still being cut (R&D guided $2.9B, SG&A $1.0B) and year-end cash is guided $4.7–5.2B after the settlement.
Valuation Score
At $174.38 the stock has nearly tripled from the $62.96 close before the INTerpath-001 release, taking market cap to ~$70B. That is ~33× the ~$2.1B 2026 revenue guide and prices a multi-indication oncology platform, not a melanoma-only launch. 12–24 month fair value after the spike settles is the $145 base: melanoma filing in 2027 with one additional INTerpath signal. Spot sits ~20% above that base, 28% of the way toward the $250 bull. Trailing EPS is negative ($(7.98)); P/E is not a useful multiple until profitability, which is still a 2028–29 question.
The mRNA Platform, Now with a Phase 3 Oncology Proof
The competitive position rests on individualized neoantigen manufacturing plus a 50/50 Merck oncology collaboration, not on COVID vaccine share which has already collapsed:
- Intismeran: first Phase 3 mRNA cancer therapy: On August 19, 2026 Merck and Moderna reported that INTerpath-001 (1,137 patients, 2:1, resected stage IIB–IV melanoma) met recurrence-free survival and distant metastasis-free survival at a pre-specified interim versus KEYTRUDA alone — the first Phase 3 win for an individualized neoantigen therapy and the first to show a clinically meaningful improvement over KEYTRUDA monotherapy in adjuvant melanoma. Hazard ratios were not disclosed; full data go to a medical meeting and to regulators. Five-year Phase 2b (KEYNOTE-942) showed a 49% cut in recurrence or death (HR 0.51) and a 59% cut in distant metastasis or death (HR 0.411). Nine Phase 2/3 INTerpath trials are underway across melanoma, NSCLC, bladder cancer and renal cell carcinoma; adjuvant RCC Phase 2 is fully enrolled and may be the next readout.
- Personalized manufacturing, 50/50 with Merck: Each intismeran dose is built from a patient's tumor mutational signature — synthetic mRNA coding for up to 34 neoantigens inside Moderna's LNP. That workflow (sequencing → design → GMP batch per patient) is the switching cost, and it is also the scale risk: commercial adjuvant melanoma would require industrializing one-lot-per-patient manufacturing. Merck paid $250 million in 2022 to exercise its option; costs and profits are shared equally worldwide. Moderna does not own the oncology P&L outright, but it keeps the manufacturing node and the platform IP.
- Respiratory franchise after the COVID cliff: FY2025 revenue was $1.9 billion after the pandemic unwind. Spikevax, mNEXSPIKE and mRESVIA remain the cash products; mFLUSIVA (mRNA-1010) won FDA approval on August 5, 2026 for adults 50+ (traditional 50–64, accelerated 65+) for the 2026–27 season, and mCOMBRIAX (flu+COVID) is authorized in the EU. 2026 guidance is up to +10% growth, ~50/50 US/international, with ~55% of H2 recognized in Q3. Norovirus (mRNA-1403) missed early-success criteria at the Phase 3 interim and needs another cohort. The respiratory book funds the oncology build; it is not a growth engine on the scale of 2021–22.
- IP settlement and remaining legal drag: H1 2026 cost of sales included $884 million of royalties tied to a $950 million Arbutus/Genevant settlement paid in July. That cleared the largest LNP-patent overhang but left potential additional exposure of up to $1.3 billion and other ongoing litigation. Regulatory lock-in on approved vaccines is real; the COVID IP estate is no longer a free option.
Moat Verdict
Moderna is a net beneficiary of AI in the narrow sense that sequence-to-neoantigen design and trial operations compress with better models — that strengthens the process, it does not create a new moat. The AI-resilient pillars that actually matter are regulatory approvals on the respiratory franchise and the still-unapproved but now Phase-3-positive oncology dataset; both are intact, not strong. Talent and process knowledge are contestable. The COVID IP settlement showed the vulnerable side: LNP patents were never exclusive. Durability in the AI era depends on converting intismeran into approved, guideline-embedded therapy, not on software-style switching costs.
65.0 resilient · 65.0 vulnerable · 80/20 = 65.0 · = 65
Open a moat to read its note.
Physicians prescribe on trial evidence and guidelines, not a software workflow; interface learning costs do not apply to vaccines or individualized therapies.
The per-patient neoantigen design, LNP formulation and one-lot GMP workflow is vendor-owned process knowledge BioNTech and others can contest but cannot copy from a label. It is a real process moat, not a monopoly — Pfizer/BioNTech already commercialized mRNA at scale.
Moderna does not control access to a public data source; tumor sequencing for intismeran is patient-specific and contractual, not a public-data franchise.
mRNA design, LNP chemistry and personalized GMP remain specialist skills, but the post-COVID talent pool is deeper than in 2019 and BioNTech, Pfizer, CureVac and large-pharma mRNA groups compete for the same people.
Vaccines and individualized therapies are sold as labeled products, not a software-style suite; government respiratory contracts are procurement, not a bundle moat.
INTerpath-001 plus KEYNOTE-942 give Moderna and Merck the largest clinical neoantigen-response dataset in melanoma, and each commercial patient would add a tumor-to-dose record. That is compounding and hard to replicate quickly, but it is not yet a genetics-scale franchise on Regeneron Genetics Center terms — and Phase 3 HRs are still unpublished.
Spikevax, mNEXSPIKE, mRESVIA and now mFLUSIVA (FDA, Aug 5 2026) plus EU mCOMBRIAX are approved products with GMP and national-program placement. Intismeran is not yet approved. The $950M Arbutus/Genevant settlement removed the largest LNP-patent cloud but confirmed that the COVID IP estate was contestable, not a Lilly-style patent wall.
A weak data flywheel: more sequenced tumors and more T-cell-response outcomes should improve neoantigen selection. Prescriber experience with mRNA in oncology is still early. This is not a two-sided network.
Long-term government partnerships (UK, Canada, Australia) and EU joint procurement for mRESVIA embed the respiratory products in national immunization calendars. Intismeran would embed in adjuvant-melanoma pathways only after approval and guideline inclusion — that is still ahead.
Moderna is a drug and vaccine manufacturer, not the authoritative record for a customer's clinical or financial system.
Drug franchise economics come from patents and approvals (regulatoryLockIn), not a unit-cost lead from manufacturing scale.
Prescribing follows efficacy, label and formulary position, not the manufacturer's name; no brand premium independent of the approvals.
Growth Analysis
Growth Drivers
Key Risk
If FDA requires mature overall survival before accepting an intismeran filing and INTerpath-001 OS is not ready by mid-2027, and the fully enrolled Phase 2 adjuvant RCC readout (possible by year-end 2026) fails to corroborate the melanoma signal, intismeran stays a single-indication option while cash burns toward the $4.7–5.2B year-end floor — collapsing the platform multiple now in the price.
Score Derivation
80.7 base + 2.7 trajectory − 10 risk = 73
Base ~81 (12–20% CAGR, midpoint 16%) + 2.7 trajectory (intismeran and flu accelerating, respiratory stable) + 0 stable margins − 10 high residual risk (Phase 3 HRs unpublished, OS immature, other tumors unproven) ≈ 73. The COVID cliff is already in the $1.9B base, not double-counted in severity.
INTerpath program — what Phase 3 melanoma does and does not settle
Nine trials, one readout
INTerpath-001 is the first positive Phase 3 for an individualized neoantigen therapy. It de-risks adjuvant melanoma. It does not, by itself, de-risk NSCLC, bladder, kidney, or the manufacturing of one lot per patient at commercial scale.
Intismeran + KEYTRUDA beat KEYTRUDA alone on RFS and DMFS in resected stage IIB–IV melanoma at a pre-specified interim. Safety matched prior studies. Merck and Moderna will take the package to a medical meeting and to regulators.
Phase 3 hazard ratios, p-values and subgroup detail were withheld. Phase 2b five-year data (HR 0.51 RFS, HR 0.411 DMFS) set the bar investors will compare against. Overall survival continues per protocol.
Fully enrolled: adjuvant RCC Phase 2 (possible year-end 2026; flagged as potentially registrational) and adjuvant muscle-invasive bladder Phase 2. Also running: high-risk Stage 1 NSCLC Phase 3 (monotherapy and with KEYTRUDA QLEX) plus further melanoma, lung and bladder cohorts.
Worldwide 50/50 cost and profit share with Merck after the 2022 $250M option exercise. Peak-sales talk is multi-billion; Moderna keeps half, and only after approval, scale manufacturing and payer coverage. Melanoma incidence in the US is ~112,000 new cases in 2026 — adjuvant stage IIB–IV is a slice of that, not the whole TAM.
Price Scenarios (12–24 Months)
Valuation Multiples
| Trailing P/E (GAAP) | N/A |
| Forward P/E (NTM) | N/A |
| PEG Ratio | N/A |
| Price / Sales (NTM) | ~33× |
| Price / FCF | N/A |
On current sales the stock is expensive: ~33× NTM revenue for a still-unprofitable vaccine company. The multiple is a platform claim, not a respiratory claim — pre-readout the same $2.1B book was valued at ~$25B (~12×). That re-rating is only earned if intismeran files on RFS/DMFS, melanoma launches in 2027–28, and at least one more tumor type corroborates. Until Phase 3 hazard ratios are public and OS matures, the $174 print is closer to the bull path than to a melanoma-only DCF.
Approximate figures as of August 19, 2026.
Where We Are vs Targets
Loading live price…
FDA wants mature OS before filing, the RCC readout does not corroborate melanoma, and COVID vaccination rates keep falling — the platform multiple unwinds toward the pre-readout capitalization plus a modest Phase 3 premium.
- Regulators decline to file on RFS/DMFS alone and INTerpath-001 overall survival is not mature by mid-2027, pushing any melanoma launch past 2028
- The fully enrolled Phase 2 adjuvant RCC study fails to show a KEYTRUDA-like additive benefit, cutting the multi-tumor read-through that today's move priced
- FY2026 revenue misses the +10% guide as US COVID demand undershoots and mFLUSIVA's first season is formulary-constrained, with cash through the $4.7B low end of the year-end range
Intismeran files on the Phase 3 melanoma package in 2027, mFLUSIVA contributes in the 2026–27 season, and one additional INTerpath indication (RCC or bladder) produces a supportive signal — enough to hold a diversified-platform multiple without assuming NSCLC is already won.
- Merck and Moderna present INTerpath-001 HRs in line with the Phase 2b direction of effect and open FDA/EMA filing talks in 1H 2027
- FY2026 revenue lands near the +10% guide (~$2.1B) and mFLUSIVA is available for the 2026–27 US season in adults 50+
- Adjuvant RCC Phase 2 (fully enrolled) or muscle-invasive bladder Phase 2 prints a directional win by mid-2027, keeping the nine-trial program intact
Melanoma is approved on RFS/DMFS, a second tumor type hits a registrational bar, and the market treats intismeran as a multi-indication KEYTRUDA-combination franchise rather than a single-cancer vaccine.
- FDA accepts an adjuvant-melanoma filing without waiting for mature OS, and a 2027–28 approval makes intismeran the first individualized neoantigen therapy on the market
- A second INTerpath study (adjuvant RCC, which William Blair flagged as potentially registrational, or high-risk Stage 1 NSCLC) meets its primary endpoint, unlocking a multi-billion peak-sales path beyond melanoma
- Personalized manufacturing scales without a capacity bottleneck, mFLUSIVA plus mCOMBRIAX lift the respiratory floor, and the cash-burn path to 2028 profitability becomes visible